News

NEWS

LATEST NEWS

Hematology Advisor spoke with experts about the new ASH clinical practice guidelines for VTE.

New Score For Predicting VTE Risk in Multiple Myeloma Outperforms Current Guidelines

A review published in Blood highlights new approaches that are being investigated to treat PCNSL bas

Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic im

Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia

A closeup shot of a render of the DNA helix.

Clinical Relevance of Key Genetic Mutations in Primary and Secondary Myelofibrosis

Researchers compared the safety and effectiveness of apixaban and rivaroxaban in patients with VTE.

Real-World Insight on Patients With Multiple Myeloma: Results Drawn From a Large Health Plan

Novel Drug May Be Effective Against NHL, CLL

Idelalisib-Rituximab Combo Found Active in R/R CLL Regardless of Complex Karyotype

Consensus Opinion Addresses Concerns About Clinical Application of CAR-T

UPCOMING MEETINGS

December 7 – 10, 2019
American Society of Hematology Annual Meeting and Exposition
Orlando, FL

Click here to view the full calendar

DRUG NEWS FROM MPR

Investigational Therapy for Hemophilia A Granted Orphan Drug Designation

New Treatment Option Approved for Patients With Myelofibrosis

Study Investigating Rivipansel in Patients With Sickle Cell Disease Misses End Points

Nipocalimab Gets Fast-Tracked for Hemolytic Disease of the Fetus and Newborn

New Oral Therapy Approved for Iron Deficiency in Adults

FDA Greenlights New Rituxan Biosimilar

Crizanlizumab Granted Priority Review for Sickle Cell Pain Crises Prevention

Dabigatran Safe, Effective for Managing VTE in Pediatric Trials

Rivaroxaban May Be Safe, Effective for Pediatric VTE Treatment, Says Study

FDA Approves Novel Therapy for Relapsed, Refractory Multiple Myeloma

Next post in News

A scientists examines a blood sample.

ASCT May Offer Alternative for Tx of High-Risk Follicular Lymphoma